Table 1 Characteristics of individuals tested in outpatient settings with and without SGTF, 15 December 2021 to 17 January 2022 and 3 February to 17 March 2022
Characteristic | Number of individuals (%) | ||||
|---|---|---|---|---|---|
15 December 2021 to 17 January 2022 | 3 February to 17 March 2022 | ||||
No SGTF (Delta) | SGTF (Omicron) | No SGTF (BA.2) | SGTF (BA.1*) | ||
n = 23,305 | n = 222,688 | n = 1,905 | n = 12,756 | ||
Age | |||||
<1 year | 391 (1.7) | 1,174 (0.5) | 53 (2.8) | 157 (1.2) | |
1–4 years | 1,023 (4.4) | 6,579 (3.0) | 104 (5.5) | 608 (4.8) | |
5–9 years | 1,321 (5.7) | 12,235 (5.5) | 89 (4.7) | 904 (7.1) | |
10–19 years | 3,218 (13.8) | 28,510 (12.8) | 217 (11.4) | 1,432 (11.2) | |
20–29 years | 3,096 (13.3) | 37,894 (17.0) | 197 (10.3) | 1,393 (10.9) | |
30–39 years | 3,942 (16.9) | 45,165 (20.3) | 315 (16.5) | 2,421 (19.0) | |
40–49 years | 3,770 (16.2) | 37,685 (16.9) | 271 (14.2) | 2,090 (16.4) | |
50–59 years | 3,310 (14.2) | 29,205 (13.1) | 272 (14.3) | 1,624 (12.7) | |
60–69 years | 1,973 (8.5) | 15,767 (7.1) | 230 (12.1) | 1,240 (9.7) | |
70–79 years | 802 (3.4) | 5,946 (2.7) | 102 (5.4) | 632 (5.0) | |
≥80 years | 264 (1.1) | 1,564 (0.7) | 39 (2.0) | 218 (1.7) | |
Sex | |||||
Female | 12,926 (55.5) | 123,227 (55.3) | 1,040 (54.6) | 6,844 (53.7) | |
Male | 10,379 (44.5) | 99,461 (44.7) | 865 (45.4) | 5,912 (46.3) | |
Race/ethnicity | |||||
White, non-Hispanic | 5,788 (24.8) | 49,411 (22.2) | 504 (26.5) | 3,354 (26.3) | |
Black, non-Hispanic | 1,552 (6.7) | 17,066 (7.7) | 109 (5.7) | 737 (5.8) | |
Hispanic | 11,792 (50.6) | 111,574 (50.1) | 858 (45.0) | 6,041 (47.4) | |
Asian/Pacific Islander | 1,954 (8.4) | 23,406 (10.5) | 256 (13.4) | 1,489 (11.7) | |
Other, mixed race or unknown race | 2,219 (9.5) | 21,231 (9.5) | 178 (9.3) | 1,135 (8.9) | |
Community median incomea | |||||
<$50,000 | 3,427 (15.0) | 34,364 (15.7) | 306 (16.5) | 1,950 (15.6) | |
$50,000–$99,999 | 14,271 (62.4) | 133,710 (60.9) | 1,059 (57.1) | 7,459 (59.7) | |
$100,000–$149,999 | 4,613 (20.2) | 45,318 (20.6) | 445 (24.0) | 2,694 (21.6) | |
≥$150,000 | 551 (2.4) | 6,131 (2.8) | 46 (2.5) | 390 (3.1) | |
Cigarette smokinga | |||||
Never smoker | 14,172 (81.3) | 134,059 (81.7) | 1,120 (79.0) | 7,796 (80.8) | |
Current smoker | 723 (4.1) | 6,865 (4.2) | 63 (4.4) | 340 (3.5) | |
Former smoker | 2,535 (14.5) | 23,150 (14.1) | 234 (16.5) | 1,512 (15.7) | |
Body mass index (kg m−2)a | |||||
Underweight (<18.5) | 1,808 (10.2) | 14,647 (8.8) | 156 (10.4) | 1,226 (12.0) | |
Normal weight (18.5–24.9) | 4,138 (23.3) | 41,117 (24.8) | 374 (24.9) | 2,436 (23.8) | |
Overweight (25.0–29.9) | 4,955 (27.9) | 46,796 (28.2) | 441 (29.4) | 2,895 (28.3) | |
Obese (≥30) | 6,863 (38.6) | 63,212 (38.1) | 530 (35.3) | 3,669 (35.9) | |
Prior year outpatient visits | |||||
0–4 | 7,973 (34.2) | 80,388 (36.1) | 480 (25.2) | 3,518 (27.6) | |
5–9 | 6,190 (26.6) | 61,656 (27.7) | 465 (24.4) | 3,343 (26.2) | |
10–14 | 3,504 (15.0) | 31,883 (14.3) | 333 (17.5) | 1,990 (15.6) | |
15–19 | 1,948 (8.4) | 17,634 (7.9) | 183 (9.6) | 1,270 (10.0) | |
≥20–29 | 3,690 (15.8) | 31,127 (14.0) | 444 (23.3) | 2,635 (20.7) | |
Prior year emergency department visits | |||||
0 | 18,402 (79.0) | 184,658 (82.9) | 1,434 (75.3) | 10,264 (80.5) | |
1 | 3,340 (14.3) | 27,489 (12.3) | 302 (15.9) | 1,704 (13.4) | |
2 | 957 (4.1) | 6,632 (3.0) | 98 (5.1) | 467 (3.7) | |
≥3 | 606 (2.6) | 3,909 (1.8) | 71 (3.7) | 321 (2.5) | |
Prior year inpatient admissions | |||||
0 | 22,497 (96.5) | 216,532 (97.2) | 1,829 (96.0) | 12,265 (96.2) | |
1 | 431 (1.8) | 3,330 (1.5) | 34 (1.8) | 254 (2.0) | |
2 | 209 (0.9) | 1,388 (0.6) | 19 (1.0) | 115 (0.9) | |
≥3 | 168 (0.7) | 1,438 (0.6) | 23 (1.2) | 122 (1.0) | |
Charlson comorbidity index | |||||
0 | 18,502 (79.4) | 181,317 (81.4) | 1,455 (76.4) | 9,884 (77.5) | |
1–2 | 3,836 (16.5) | 34,691 (15.6) | 336 (17.6) | 2,231 (17.5) | |
3–5 | 710 (3.0) | 5,051 (2.3) | 74 (3.9) | 466 (3.7) | |
≥6 | 257 (1.1) | 1,629 (0.7) | 40 (2.1) | 175 (1.4) | |
Prior SARS-CoV-2 infectionb | |||||
No documented prior infection | 23,221 (99.6) | 221,525 (99.5) | 1,898 (99.6) | 12,681 (99.4) | |
Documented prior infection | 84 (0.4) | 1,163 (0.5) | 7 (0.4) | 75 (0.6) | |
COVID-19 vaccination | |||||
Unvaccinated | 9,802 (42.1) | 65,480 (29.4) | 594 (31.2) | 3,858 (30.2) | |
Ad.26.COV2.S—1 dose | 717 (3.1) | 6,874 (3.1) | 34 (1.8) | 273 (2.1) | |
Ad.26.COV2.S—with any booster dose | 170 (0.7) | 2,329 (1.0) | 38 (2.0) | 203 (1.6) | |
BNT162b2 or mRNA-1273—1 dose | 646 (2.8) | 6,266 (2.8) | 33 (1.7) | 287 (2.2) | |
BNT162b2 or mRNA-1273—2 doses (≥180 days prior) | 7,492 (32.1) | 81,266 (36.5) | 424 (22.3) | 2,826 (22.2) | |
BNT162b2 or mRNA-1273—2 doses (91–180 days prior) | 1,600 (6.9) | 18,409 (8.3) | 94 (4.9) | 863 (6.8) | |
BNT162b2 or mRNA-1273—2 doses (≤90 days prior) | 622 (2.7) | 8,548 (3.8) | 47 (2.5) | 625 (4.9) | |
BNT162b2 or mRNA-1273—3 doses | 2,256 (9.7) | 33,516 (15.1) | 641 (33.6) | 3,821 (30.0) | |
